go-v.orgdoi

IMP-4--Producing Pseudomonas aeruginosa in a French Patient Repatriated from Malaysia: Impact of Early Detection and Control Measures

Frédéric Bert, Dominique Vanjak, Véronique Leflon‐Guibout, Serge Mrejen, S. Delpierre, A Redondo, Marie-Hélène Nicolas-Chanoine · Clinical Infectious Diseases · 2007

  • DOI 10.1086/511693
  • Publisher Oxford University Press
  • Type article
  • Issued 2007

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Infectious Diseases · Oxford University Press · article · 2007

Abstract

TO THE EDITOR—We read with great interest the article by Peleg et al. [1] that reported on an outbreak of bacterial strains that produced the metallo-β-lactamase (MBL) gene IMP-4 in an Australian hospital. In 2004, they identified the blaIMP-4 gene—which had been previously described in Acinetobacter species and Citrobacter youngae isolates from Hong Kong and China [2, 3]—in a Pseudomonas aeruginosa isolate in Australia [4]. After this identification, the gene rapidly disseminated in their hospital, resulting in an outbreak involving 5 different gram-negative species [1].

As indicated by Rossolini in the editorial commentary of the same issue [5], blaIMP-4 was likely imported from Southeast Asia via international travelers, which underscores the role of human movement in the intercontinental spread of MBL genes. In this letter, we report an IMP-4–producing P. aeruginosa isolate from a French patient repatriated from Malaysia, and we describe strategies of detection and infection control used for preventing its intrahospital dissemination.

Before being repatriated to France in August 2006, the 75-year-old patient had been hospitalized in an intensive care unit in Malaysia for 23 days following a cerebrovascular accident and had received multiple antibiotic therapies, including a 12-day course of meropenem for pneumonia. On admission to the emergency department of our hospital, the patient presented with right hemiplegia; had a tracheotomy canula, a urinary catheter, and a nasogastric tube; and was receiving oral amoxicillin-clavulanate. Because of his prior hospitalization, a rectal swab was immediately performed for detection of multiresistant bacteria.

Culture yielded a multiresistant P. aeruginosa isolate with an unusual β-lactam phenotype that was characterized by resistance to ticarcillin, ceftazidime, and imipenem (MIC, >32 mg/L); intermediate susceptibility to aztreonam; and susceptibility to piperacillin. Such a phenotype suggested MBL production, which was confirmed by the imipenem-EDTA double-disk synergy test [6]. The MBL determinant was subsequently identified as blaIMP-4 by molecular techniques [7]. The patient, who had just been transferred to the neurosurgery department, was moved to a single room, and contact barriers were implemented.

Antibiotic treatment was discontinued, and invasive devices were removed as soon as possible to decrease the risk factors for P. aeruginosa infection. Forty days after admission, when discharge from the hospital was scheduled, a rectal swab was performed and determined to be negative for IMP-4–producing isolates. However, isolation measures were maintained until discharge, 20 days later. No further MBL-producing isolate has been identified in our hospital so far. MBL genes are widespread in some geographical areas, particularly Southeast Asia, whereas they remain uncommon in other countries [8].

So far, very few MBLs have been reported in France, and all of those that have been identified were Veronese imipenemase–type enzymes [9, 10]. Our report highlights the importance of an active surveillance strategy in countries where MBLs are absent or uncommon. Patients transferred from high-risk areas should be screened on admission, and isolation precautions should be implemented until culture results are available. Such measures are critical to prevent these enzymes from spreading worldwide, as occurred with extended-spectrum β-lactamases. Potential conflicts of interest. All authors: no conflicts.

Open the resolved locator · 10.1086/511693

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:58 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.1086/511693
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.